ICTMM

[September 23-27, 2012]
Rio de Janeiro, Brazil

DNDi hosted 3 sessions at the XVIII International Congress for Tropical Medicine and Malaria.

 


Cocktail Reception: Product Development Partnerships (PDPs) for Neglected Diseases
Closed session: 24 September, 19h-19h30
Co-hosted by the Medicines for Malaria Venture (MMV) and DNDi

See invitation
See programme

 

Progressing NCEs through clinical development for the treatment of neglected tropical diseases
Session I: 25 September, 09h00-11h00

Chair: Els Torreele, Director of the Public Health Program’s Access to Essential Medicines Initiative, Open Society Foundation

Abstract: This session aimed to give an overview of the realities of developing new drugs for the treatment of neglected tropical diseases, and to present DNDi’s model of progressing NCEs through the development pipeline, with a focus on the main element of success, strong partnerships. 
[complete abstract PDF]
Topics:

High throughput screening
Lucio Freitas-Junior, IPK

SCYX-7158: an oxaborole entering Phase I for the treatment of HAT (sleeping sickness) 
Antoine Tarral, Head of HAT Clinical Program, DNDi

E1224 for Chagas disease: news on a drug candidate from a promising class 
Isabela Ribeiro, Head of DNDi’s Clinical Programme in Chagas disease & Frederick Duncanson, Eisai

Nitroimidazoles as a potential new series for visceral leishmaniasis – Fexinidazole and VL-2098
Shyam Sundar, Professor of Medicine, Institute of Medical Sciences Banaras Hindu University (BHU), Varanasi, India

 
 
Developing safe and efficacious drugs to treat Chagas disease
Session II: 25 September, 16h45-18h45
Chair: I
sabela Ribeiro, Head of Chagas Clinical Program,
DNDi Abstract: The session explored the current state of the Chagas disease portfolio and gave an overview of what is needed to provide patients with a safe, efficacious, easy-to-use and affordable treatment, with a focus on early drug discovery and assessment of treatment efficacy. 
[complete abstract PDF]
 
Topics:
 
Early medicinal chemistry to identify new candidate drugs 
Martine Keenan, Head of Drug Discovery, Epichem


Potential drug candidate series: nitroimidazoles and fenarimols
 

Eric Chatelain, Head of Chagas Discovery & Preclinical Program, DNDi

Efficacy, safety and population pharmacokinetics of benznidazole in children: presentation of results

Jaime Altcheh, Ricardo Gutiérrez Children’s Hospital

Optimization of sampling procedure for PCR technique to assess parasitological response for patients with chronic Chagas disease treated with benznidazole in Aiquile, Bolivia’ – preliminary results

Laurence Flevaud
, MSF – Spain

 

Protozoan: African Trypanosomiasis 

Workshop, 26 September, 14:00-15:30

Topics: 

Fexinidazole for HAT
Olaf Valverde, Antoine Tarral, Séverine Blesson, Virginie Gualano, Mathieu Felices, Lionel Hovsepian, Eric Evene, Pascal Voiriot, Nathalie Strub-Wourgaft

 

 

 


More information: